Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma
- 15 January 2007
- Vol. 62 (2) , 149-153
- https://doi.org/10.1111/j.1398-9995.2006.01310.x
Abstract
Background: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real‐life studies that assess the effectiveness of treatment are of particular interest. Methods: We determined the incremental cost‐effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real‐life 1‐year randomized open‐label study (ETOPA) and using Canada as a reference country. Only patients receiving high‐dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality‐adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95% confidence interval and one‐sided sensitivity analyses were performed. Results: The base case lifetime analysis of standard therapy vs standard therapy plus add‐on omalizumab for the first 5 years, gave an ICER of €31 209. Probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER was €27 739–€40 840. The ICER range for one‐way sensitivity analyses was €23 762 without discounting to €66 443 without inclusion of asthma‐related mortality. Conclusions: This study demonstrates that add‐on omalizumab therapy is cost‐effective in patients with severe persistent allergic asthma.Keywords
This publication has 27 references indexed in Scilit:
- The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to SwedenCurrent Medical Research and Opinion, 2006
- Cost‐effectiveness of asthma control: an economic appraisal of the GOAL studyAllergy, 2006
- Factors Predictive of Future Clinically Significant Exacerbations in Severe AsthmaJournal of Allergy and Clinical Immunology, 2006
- Information Created to Evade Reality (ICER)PharmacoEconomics, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthmaAnnals of Allergy, Asthma & Immunology, 2004
- Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthmaAnnals of Allergy, Asthma & Immunology, 2002